These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

890 related items for PubMed ID: 25046616

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. [Comparison of efficacy between sorafenib and sunitinib as first-line therapy for metastatic renal cell carcinoma and analyze prognostic factors for survival].
    Cai W, Yuan YC, Li MY, Kong W, Dong BJ, Chen YH, Zhang J, Xue W, Huang YR, Zhou LX, Huang JW.
    Zhonghua Zhong Liu Za Zhi; 2018 May 23; 40(5):384-389. PubMed ID: 29860767
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Multikinase inhibitors in metastatic renal cell carcinoma: indirect comparison meta-analysis.
    Leung HW, Chan AL.
    Clin Ther; 2011 Jun 23; 33(6):708-16. PubMed ID: 21704235
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Effect of the timing of best tumor shrinkage on survival of patients with metastatic renal cell carcinoma who received first-line tyrosine kinase inhibitor therapy.
    Ishihara H, Yagisawa T, Kondo T, Omae K, Takagi T, Iizuka J, Kobayashi H, Tanabe K.
    Int J Clin Oncol; 2017 Feb 23; 22(1):126-135. PubMed ID: 27549785
    [Abstract] [Full Text] [Related]

  • 8. Pazopanib after sunitinib failure in patients with metastatic renal cell carcinoma.
    Rautiola J, Utriainen T, Peltola K, Joensuu H, Bono P.
    Acta Oncol; 2014 Jan 23; 53(1):113-8. PubMed ID: 23721300
    [Abstract] [Full Text] [Related]

  • 9. [Metastasized renal cell carcinoma. Measurement of plasma levels of the tyrosine kinase inhibitors sunitinib, sorafenib and pazopanib].
    Keil C, Götze L, Olbert P, Hofmann R, Nockher WA, Hegele A.
    Urologe A; 2015 Jun 23; 54(6):811-8. PubMed ID: 25503897
    [Abstract] [Full Text] [Related]

  • 10. Occurrence of hepatotoxicity with pazopanib and other anti-VEGF treatments for renal cell carcinoma: an observational study utilizing a distributed database network.
    Shantakumar S, Nordstrom BL, Djousse L, Hall SA, Gagnon DR, Fraeman KH, van Herk-Sukel M, Chagin K, Nelson J.
    Cancer Chemother Pharmacol; 2016 Sep 23; 78(3):559-66. PubMed ID: 27438066
    [Abstract] [Full Text] [Related]

  • 11. Rationale and protocol of SOAP: a phase II study to evaluate the efficacy of sorafenib as second-line treatment after pazopanib in patients with advanced renal cell carcinoma.
    Iacovelli R, Verzoni E, Grassi P, Farcomeni A, de Braud F, Procopio G.
    Tumori; 2014 Sep 23; 100(6):e282-5. PubMed ID: 25688511
    [Abstract] [Full Text] [Related]

  • 12. Efficacy and safety of sorafenib versus sunitinib as first-line treatment in patients with metastatic renal cell carcinoma: largest single-center retrospective analysis.
    Sheng X, Chi Z, Cui C, Si L, Li S, Tang B, Mao L, Lian B, Wang X, Yan X, Guo J.
    Oncotarget; 2016 May 10; 7(19):27044-54. PubMed ID: 26894858
    [Abstract] [Full Text] [Related]

  • 13. Sorafenib or sunitinib as postoperative adjuvant therapy for Chinese patients with locally advanced clear cell renal cell carcinoma at high risk for disease recurrence.
    Zhao J, Zhu Y, Zhang C, Wang X, He H, Wang H, Wu Y, Zhou W, Shen Z.
    Urol Oncol; 2013 Nov 10; 31(8):1800-5. PubMed ID: 22658883
    [Abstract] [Full Text] [Related]

  • 14. SWITCH: A Randomised, Sequential, Open-label Study to Evaluate the Efficacy and Safety of Sorafenib-sunitinib Versus Sunitinib-sorafenib in the Treatment of Metastatic Renal Cell Cancer.
    Eichelberg C, Vervenne WL, De Santis M, Fischer von Weikersthal L, Goebell PJ, Lerchenmüller C, Zimmermann U, Bos MM, Freier W, Schirrmacher-Memmel S, Staehler M, Pahernik S, Los M, Schenck M, Flörcken A, van Arkel C, Hauswald K, Indorf M, Gottstein D, Michel MS.
    Eur Urol; 2015 Nov 10; 68(5):837-47. PubMed ID: 25952317
    [Abstract] [Full Text] [Related]

  • 15. Antitumor effects of sunitinib or sorafenib in patients with metastatic renal cell carcinoma who received prior antiangiogenic therapy.
    Tamaskar I, Garcia JA, Elson P, Wood L, Mekhail T, Dreicer R, Rini BI, Bukowski RM.
    J Urol; 2008 Jan 10; 179(1):81-6; discussion 86. PubMed ID: 17997441
    [Abstract] [Full Text] [Related]

  • 16. First-line therapy for treatment-naive patients with advanced/metastatic renal cell carcinoma: a systematic review of published randomized controlled trials.
    Takyar S, Diaz J, Sehgal M, Sapunar F, Pandha H.
    Anticancer Drugs; 2016 Jun 10; 27(5):383-97. PubMed ID: 26886011
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 45.